28.64USD+3.51%Mkt Cap: 2.95B USDP/E: —Last update: 2026-05-22
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap2.95B USD
Enterprise Value1.79B USD
Revenue (TTM)164.01M USD
Gross Profit-240.93M USD
Net Income (TTM)-79.99M USD
Revenue/Share1.597 USD
Last Price28.64 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees522
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.83
PEG—
EV/EBITDA-5.13
EV/Revenue10.93
P/S17.36
P/B2.36
EPS (TTM)-0.49
EPS (Forward)-4.74
52W Range
15.3563% of range36.44
52W High36.44 USD
52W Low15.35 USD
Profitability
Gross Margin-146.90%
Oper. Margin-337.81%
EBITDA Margin-212.94%
Profit Margin-57.24%
ROE-6.46%
ROA-5.40%
Growth
Revenue Growth324.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-345.10M USD
CapEx (TTM)14.95M USD
FCF Margin-142.40%
FCF Yield-7.93%
Net Debt-960.83M USD
Net Debt/EBITDA2.75
Balance Sheet
Debt/Equity0.12
Current Ratio16.99
Quick Ratio16.25
Book Value/Sh11.71 USD
Cash/Share12.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)51.07 USD
Target Range26.00 USD – 80.00 USD
# Analysts15
Ownership
Shares Out.102.88M
Float87.97M
Insiders1.36%
Institutions107.06%
Short Interest
Short Ratio9.7d
Short % Float31.53%
Short % Out.20.35%
Shares Short20.94M
Short (prev mo.)23.36M
Technical
SMA 5027.75 (+3.2%)
SMA 20025.68 (+11.5%)
Beta2.26
S&P 52W Chg28.31%
Avg Vol (30d)2.15M
Avg Vol (10d)2.16M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—